Dr. Pusztai on Evolution of Treatment for HER2+ Breast Cancer

Lajos Pustzai, MD, DPhil
Published: Monday, Sep 19, 2016


Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved over time.

One of the first successful examples of treatment for this patient population is trastuzumab (Herceptin), Pusztai explains.

In the wake of this agent's development, two more promising therapies have been added to the field, which are pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1). These drugs have demonstrated efficacy in both the early-stage and late-stage settings, he adds.

Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved over time.

One of the first successful examples of treatment for this patient population is trastuzumab (Herceptin), Pusztai explains.

In the wake of this agent's development, two more promising therapies have been added to the field, which are pertuzumab (Perjeta) and ado-trastuzumab emtansine (T-DM1). These drugs have demonstrated efficacy in both the early-stage and late-stage settings, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x